MedTrace Logo

Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition

NCT01052896 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-10-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of gabapentin on symptom control in patients with defined functional dyspepsia refractory to conventional proton pump inhibitor therapy and to compare these effects to that of placebo.

Conditions

  • Functional Dyspepsia

Interventions

DRUG

Gabapentin

300mg po TID

DRUG

Placebo

Look-alike of gabapentin 300mg given po tid

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • 59th Medical Wing

    lead FED

Principal Investigators

  • Jeffrey W Molloy, MD · Gastroenterology Division - SAMMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-03-31
Completion
2012-08-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052896 on ClinicalTrials.gov